# LEAP-005 (NCT03797326)

> Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03797326
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Cancer; Glioblastoma; Biliary Tract Cancers; Pancreatic Cancer
- Interventions: Pembrolizumab; Lenvatinib
- Enrollment: 611
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
- Primary outcome: Number of Participants With One or More Adverse Events (AEs)
- Primary outcome: Number of Participants Who Discontinued From Study Treatment Due to an AE

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- Podcasts: 3
- YouTube: 2
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=leap-005-nct03797326

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03797326", "email": "<work email>"}; the inbox owner confirms by the emailed link.